These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 15136116)

  • 1. "First uterine pass effect" is observed when estradiol is placed in the upper but not lower third of the vagina.
    Cicinelli E; De Ziegler D; Morgese S; Bulletti C; Luisi D; Schonauer LM
    Fertil Steril; 2004 May; 81(5):1414-6. PubMed ID: 15136116
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Postmenopausal atrophic colpitis--its local treatment with low-dose estradiol].
    Rachev E
    Akush Ginekol (Sofiia); 1995; 34(1):41-2. PubMed ID: 7485806
    [No Abstract]   [Full Text] [Related]  

  • 3. An open-label randomized trial to determine the most effective regimen of vaginal estrogen to reduce the prevalence of atrophic changes reported in postmenopausal cervical smears.
    Bateson DJ; Weisberg E
    Menopause; 2009; 16(4):765-9. PubMed ID: 19407678
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Levels of tibolone and estradiol and their nonsulfated and sulfated metabolites in serum, myometrium, and vagina of postmenopausal women following treatment for 21 days with tibolone, estradiol, or estradiol plus medroxyprogestrone acetate.
    Verheul HA; Blok LJ; Burger CW; Hanifi-Moghaddam P; Kloosterboer HJ
    Reprod Sci; 2007 Feb; 14(2):160-8. PubMed ID: 17636227
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Placement of the vaginal 17beta-estradiol tablets in the inner or outer one third of the vagina affects the preferential delivery of 17beta-estradiol toward the uterus or periurethral areas, thereby modifying efficacy and endometrial safety.
    Cicinelli E; Di Naro E; De Ziegler D; Matteo M; Morgese S; Galantino P; Brioschi PA; Schonauer A
    Am J Obstet Gynecol; 2003 Jul; 189(1):55-8. PubMed ID: 12861138
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Vagifem. A new low-dosage estradiol preparation for local treatment of postmenopausal urogenital atrophy].
    Eriksen PS; Rasmussen H
    Ugeskr Laeger; 1992 Apr; 154(16):1122-4. PubMed ID: 1523727
    [No Abstract]   [Full Text] [Related]  

  • 7. Low dose of transdermal estradiol gel for treatment of symptomatic postmenopausal women: a randomized controlled trial.
    Simon JA; Bouchard C; Waldbaum A; Utian W; Zborowski J; Snabes MC
    Obstet Gynecol; 2007 Mar; 109(3):588-96. PubMed ID: 17329509
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Uterine and vaginal effects of unopposed ultralow-dose transdermal estradiol.
    Johnson SR; Ettinger B; Macer JL; Ensrud KE; Quan J; Grady D
    Obstet Gynecol; 2005 Apr; 105(4):779-87. PubMed ID: 15802405
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A study of 17beta-estradiol-regulated genes in the vagina of postmenopausal women with vaginal atrophy.
    Cotreau MM; Chennathukuzhi VM; Harris HA; Han L; Dorner AJ; Apseloff G; Varadarajan U; Hatstat E; Zakaria M; Strahs AL; Crabtree JS; Winneker RC; Jelinsky SA
    Maturitas; 2007 Dec; 58(4):366-76. PubMed ID: 17997058
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transdermal estradiol gel 0.1% for the treatment of vasomotor symptoms in postmenopausal women.
    Hedrick RE; Ackerman RT; Koltun WD; Halvorsen MB; Lambrecht LJ
    Menopause; 2009; 16(1):132-40. PubMed ID: 18971794
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomized comparison of lower and standard dosages of transdermal estradiol on serum estradiol levels and vaginal maturation index.
    Rungruxsirivorn T; Panyakamlerd K; Trerattanachart S; Taechakraichana N
    J Med Assoc Thai; 2006 Sep; 89(9):1362-7. PubMed ID: 17100370
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Microdose transdermal estrogen therapy for relief of vulvovaginal symptoms in postmenopausal women.
    Bachmann GA; Schaefers M; Uddin A; Utian WH
    Menopause; 2009; 16(5):877-82. PubMed ID: 19458560
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Postmenopausal vaginal atrophy correlates with decreased estradiol and body mass index and does not depend on the time since menopause.
    Repse-Fokter A; Takac I; Fokter SK
    Gynecol Endocrinol; 2008 Jul; 24(7):399-404. PubMed ID: 18645712
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of low-dose estradiol vaginal tablets in the treatment of atrophic vaginitis: a randomized controlled trial.
    Bachmann G; Lobo RA; Gut R; Nachtigall L; Notelovitz M
    Obstet Gynecol; 2008 Jan; 111(1):67-76. PubMed ID: 18165394
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of estradiol valerate and levonorgestrel on vaginal health.
    Manonai J; Chittacharoen A; Theppisai U
    Eur J Obstet Gynecol Reprod Biol; 2004 Aug; 115(2):190-3. PubMed ID: 15262354
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of transdermal and vaginal estrogen therapy on markers of postmenopausal estrogen status.
    Gupta P; Ozel B; Stanczyk FZ; Felix JC; Mishell DR
    Menopause; 2008; 15(1):94-7. PubMed ID: 17882008
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of one-week treatment with vaginal estrogen preparations on serum estrogen levels in postmenopausal women.
    Labrie F; Cusan L; Gomez JL; Côté I; Bérubé R; Bélanger P; Martel C; Labrie C
    Menopause; 2009; 16(1):30-6. PubMed ID: 18820592
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Management of post-menopausal vaginal atrophy and atrophic vaginitis.
    Castelo-Branco C; Cancelo MJ; Villero J; Nohales F; Juliá MD
    Maturitas; 2005 Nov; 52 Suppl 1():S46-52. PubMed ID: 16139449
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of intravaginal dehydroepiandrosterone (Prasterone) on libido and sexual dysfunction in postmenopausal women.
    Labrie F; Archer D; Bouchard C; Fortier M; Cusan L; Gomez JL; Girard G; Baron M; Ayotte N; Moreau M; Dubé R; Côté I; Labrie C; Lavoie L; Berger L; Gilbert L; Martel C; Balser J
    Menopause; 2009; 16(5):923-31. PubMed ID: 19424093
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomized, multicenter, double-blind, placebo-controlled trial to evaluate the efficacy and safety of synthetic conjugated estrogens B for the treatment of vulvovaginal atrophy in healthy postmenopausal women.
    Simon JA; Reape KZ; Wininger S; Hait H
    Fertil Steril; 2008 Oct; 90(4):1132-8. PubMed ID: 18053998
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.